trending Market Intelligence /marketintelligence/en/news-insights/trending/qke-qkjosuffm3t6ssj2bw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Bluebird Bio closes $632.5M common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Bluebird Bio closes $632.5M common stock offering

Bluebird Bio Inc. closed an underwritten public offering for gross proceeds of about $632.5 million.

The Cambridge, Mass.-based biotechnology company sold 3,892,308 common shares at $162.50 apiece. Shares issued include 507,692 common shares sold as part of the full exercise of the underwriters' overallotment option.

Goldman Sachs & Co. LLC, BofA Merrill Lynch, J.P. Morgan Securities LLC and Cowen acted as joint book-running managers, with Wells Fargo Securities as co-manager of the offering.

Bluebird Bio develops gene therapies for severe genetic diseases and cancer.